Avalyn Pharma Inc. Common Stock

AVLN

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$38.48

+$1.24 · +3.34%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

42/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Weakening

Sentiment

Bullish

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Lyn Baranowski
Listed since: Apr 30, 2026
Employees: 55

Market position

Volume: 159.5K; 0.32× average
Average volume: 496.27K; Average daily volume
Market cap: 1.7B USD
Beta: -1.13; Market reference 1

Earnings

Latest fiscal-year EPS: -2.04; FY2025
Latest fiscal-year revenue: 0 USD; FY2025
Next fiscal-year EPS consensus: -3.12; FY2026 · 2 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$60.00

56.37% upside

Past 12 months12-month forecast

Price history unavailable

High $80.00Average $60.00Low $51.00

Recent analyst actions

1 institution

Morgan StanleymaintainOverweightAug 13, 2026

AVLN news

globenewswire.comAug 12, 2026

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress,…

Read source

globenewswire.comJun 17, 2026

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027

Read source

marketbeat.comJun 5, 2026

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position…

Read source

globenewswire.comJun 3, 2026

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability…

Read source

globenewswire.comMay 27, 2026

Avalyn to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory…

Read source